Stellus Rx, LLC

Stellus Rx, LLC, based in the US, specializes in pharmacist-led health support services that enhance patient care quality and optimize pharmacy experiences through tailored solutions. Stellus Rx, LLC provides pharmacist-led health support services aimed at improving patient experiences and healthcare outcomes. Founded in 2022, the company is headquartered in Plano, Texas, US. Stellus Rx has engaged in one investment deal, with the most recent transaction taking place on December 8, 2025, involving WindRose Health Investors.

Financial details of this investment have not been disclosed. Stellus Rx specializes in pharmacist-led health support services, focusing on personalized pharmacy expertise to improve care quality and patient experiences. The company's core offerings include medication access solutions, educational resources, and adherence programs designed to enhance health outcomes while reducing overall healthcare costs. Stellus Rx serves a diverse clientele comprising patients, healthcare providers, employer groups, and risk-bearing entities, aiming to redefine the pharmacy experience in the United States.

Their services are grounded in a shared purpose and leverage pharmacist-led teams to connect with patients at critical moments, ensuring that medication management is both effective and accessible. Stellus Rx operates primarily within the United States, providing its innovative pharmacy services to a wide geographical market that includes various states, thereby addressing the national healthcare landscape. Stellus Rx generates revenue through a combination of service fees and partnerships with various healthcare organizations. The transactions typically involve direct engagement with employers and health plans, wherein Stellus Rx provides tailored pharmacy services that align with clients' specific needs.

Under this structure, employers may subscribe to Stellus Rx’s services, which include extensive medication management and adherence solutions. This subscription-based model enhances patient outcomes and decreases costs, ultimately benefiting both the employer and their employees. Specific pricing plans are determined based on the scope of services provided, reflecting the company's commitment to delivering high-quality pharmacy care through its flagship offerings like Stellus Adhere and Stellus Engage. In December 2025, Stellus Rx plans to utilize the recent investment from WindRose Health Investors to expand its operational capabilities and market reach.

The company is focused on developing new products and enhancing its pharmacy services, although specific product launches have not been disclosed. Stellus Rx aims to enter new geographic markets that are currently being identified, with plans to initiate this expansion in the coming years.